{
  "trial_id": "NCT04084769",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Participants participated in and completed study MET50 (MET50 Groups 1, 2, or 3 only)",
      "label": "met"
    },
    {
      "criterion": "For Group 2 only (Menveo vaccine-primed participants only; enrichment population):",
      "label": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "Participant is pregnant, or lactating, or of childbearing potential and not using an effective method of contraception or abstinence from at least 4 weeks prior to the first vaccination until at least 4 weeks after the last vaccination.",
      "label": "unknown"
    },
    {
      "criterion": "Receipt of any vaccine in the 4 weeks (28 days) preceding the trial vaccination or planned receipt of any vaccine before Visit 3 except for influenza vaccination, which may be received at least 2 weeks before study investigational vaccine",
      "label": "triggers"
    }
  ],
  "notes": "The patient has high blood pressure and signs of septicemia. He was diagnosed with atypical hemolytic uremic syndrome.",
  "_meta": {
    "topic_id": "68",
    "trial_id": "NCT04084769",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}